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Summary
Background Inferences  about  long-term effects of  therapies  in  multiple  sclerosis
(MS)  have  been  based  on  surrogate  markers  studied  in  short-term  trials.
Nevertheless,  MS trials  have  been  getting  steadily  shorter  despite  the  lack  of  a
consensus  definition  for  the  most  important  clinical  outcome  -  unremitting
progression of disability.
Methods We have examined widely used surrogate markers of disability progression
in MS within a unique database of individual patient data from the placebo arms of
31 randomised clinical trials.
Findings Definitions of treatment failure used in secondary progressive MS trials
include much change unrelated to the target of unremitting disability. In relapsing-
remitting MS, disability progression by treatment failure definitions was no more
likely than similarly defined improvement for these disability surrogates. Existing
definitions of disease progression in relapsing-remitting trials encompass random
variation,  measurement error and remitting relapses and appear not to measure
unremitting disability.
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Interpretation  Clinical  surrogates  of  unremitting  disability  used  in  relapsing
-remitting trials cannot be validated. Trials have been too short and/or degrees of
disability change too small to evaluate unremitting disability outcomes. Important
implications  for  trial  design  and  reinterpretation  of  existing  trial  results  have
emerged long after regulatory approval  and widespread use of  therapies in  MS,
highlighting the necessity of having primary trial data in the public domain.
Introduction 
The natural history of multiple sclerosis (MS) evolves over some 30-40 years1. The most
important therapeutic target is unremitting disability occurring in the progressive phase of
the disease.  A secondary progressive phase (hereafter  SPMS)  supervenes  in >80% of
relapsing-remitting patients and after 15-18 years, some 50% of patients need assistance
to  walk,  are  confined  to  wheelchair,  bed  or  have  died2.  Maintaining
randomisation/placebo arms beyond 2-3 years in individuals of reproductive age has been
difficult. In this condition where therapeutic disappointment is familiar, regular reports
have appeared from short-term trials showing treatment effects on surrogate markers3.
These studies highlight problems common to many chronic diseases in extrapolating from
short-term surrogates.
  Unremitting  disability  is  the  outcome  most  relevant  yet  least  clearly  measured  in
relapsing-remitting MS (hereafter  RRMS).  Relapses,  short-term disability change,  and
magnetic resonance imaging (MRI) are surrogates for this. No consensus definition of
disability accumulation can be found in trials leading to approved therapies. On a 10-
point  scale (EDSS - expanded disability status  scale) unconfirmed and confirmed (by
repeated serial in-trial observations - see below) changes of 0.5 and 1.0 point have been
used as primary and secondary outcomes in studies with results  leading to  regulatory
approval.  Longer  term  data  have  been  unavailable4,5 or  dropouts  have  compromised
interpretation6,7.  Meanwhile,  dependence  on  inferences  from  short-term  measures  of
relapses, “disability” and from MRI-based surrogate markers has continued both for pilot
and phase 2/3  studies.  SPMS is  characterised  by more  advanced EDSS levels  where
variation  is  less  than  in  RRMS8.  However,  the  course  of  SPMS  has  been  largely
intractable to therapy9,10,11. The dearth of long-term outcome data stimulated this study,
aimed at identifying reliable markers or surrogates of long-term disease progression.
Materials and methods
Centre description 
The Sylvia Lawry Centre for Multiple Sclerosis Research (hereafter SLC) was established
in February 2001 to support independent research into MS natural history and clinical
trial methodology in order to accelerate development of effective therapies. This unique
database consisted of the placebo arms from 31 treatment trials. See http://www.slcmsr.info
for further information.
Dataset 
Analyses are based on the assembled SLCMSR data set of RR and SP patients from 31
trials. This is split into open (40% -1344 patients), closed (50%) and reserve (10%) parts,
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the latter two as a reservoir for confirmation of results. Clinical trials were of one to five
years’ duration (most <2-3 years) with planned 3-6 monthly assessments. 
Patient selection 
We defined 3 data subsets:
  Subset 1- RR and SP MS patients observed for at least 15 months, having uninterrupted
serial assessments every three months ( 1 month) and with EDSS at baseline below 6.0
-.  This  was  necessary in  order  to  compare  different  definitions  of  ‘time to  sustained
progression’.
  Subset  2 had one observation two years ( 1 month)  after  entry into the study but
without any further restrictions.
 Subset 3 comprised those who were thought to have measurements taken during relapses.
  The characteristics of the subsets are listed in Table 1, by RR and SPMS phenotype.
From the original 1344 placebo patients in the open dataset, 425 patients entered subset 1
and 516 entered subset 2. Truncating data to simulate a 2-year trial minimises the impact
of dropouts and exclusions which rapidly accelerate after this duration. 
Replication 
This was carried out for the most stringent definition of progression (1 point confirmed at
6 months) in an independent, randomly selected, matched group in the closed dataset. 
Outcome criteria 
These  were  the  definitions  of  unconfirmed  or  confirmed disability  change of  0.5-1.0
EDSS points used in the database trials. Confirmation times of 3-6 months, added to the
3-month  minimal  period  for  a  change  to  register,  shorten  the  effective  period  of
observation. Few studies required additional visits after study conclusion, so the last on-
study visit could only be used for confirmation.
Definitions  of  worsening  (trial  defined  ‘treatment  failure’  or  TF)  and  placebo
‘treatment improvement’ (TI)
Using  the  EDSS  scale,  we  examined:  1)  0.5  points  minimum  increase
unconfirmed/confirmed,  2)  1.0  minimum  increase  unconfirmed/confirmed.  EDSS
changes  sustained  at  90  days  or  180  days  as  in  the  trials  the  change  were  deemed
confirmed. Improvement was a decrease in the same defined scores.
Clinical phenotype definitions 
This was defined as in the RR and SP trials constituting the dataset.
Sensitivity of these measures
Trial-employed definitions of disability worsening have been widely accepted for clinical
decision-making.  To  test  the  validity of  these  definitions  of  worsening  or  ‘treatment
failure’, we examined placebo arms from the 31 trials, generally reported to have been
stable  for  at  least  1-3  months  at  baseline.  We  reasoned  that  the  difference  between
probabilities of significant improvement vs significant worsening would approximate the
proportion of worsening attributable to noise from random variation/measurement error.
Data were also analysed omitting the first point, effectively extending the effective period
of prestudy stability to > 4-6 months.
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Methods of analysis 
For  perspective  on  within-trial  changes  for  EDSS,  we  calculated  events  meeting  the
selected outcome criteria. Proportions of opposite events with same EDSS change and
confirmation period were calculated. Since MS trials typically have used Kaplan-Meier
curves to describe the accumulation of disability, these were plotted for definitions of
worsening and improvement  used in the trials  studied and p-values from a two-sided
logrank test  were computed.  Additionally, one-sided Wilcoxon signed rank tests  were
used to compare absolute differences in EDSS over one and two years. 
Results
Clinical characteristics of the 3 database subsets are in Table 1 showing representative
characteristics of trial-eligible RR and SP patients.
Table 1 near here if possible on left facing page along with Table 2 and 3.
Defined EDSS change by time in study    
We calculated worsening (meeting treatment failure definitions) and improvement (same
definition  but  opposite  polarity) and counted events  in  RR and SP for  each of the 6
periods of confirmation/non confirmation using all available data for subset 1 without
truncation  -  shown  in  Table  2.  In  SP,  worsening  occurred  more  frequently  than
improvement and was less and less likely to remit with increased stringency of definition.
However, even in SP, improvement occurred 53% as often as worsening (Table 2). For
RR however, event frequencies were similar for all definitions and sustainability was also
similar for less stringent definitions. The longer the confirmation period, the fewer were
the events and overall, the lower the likelihood of reversion, but only a trend is seen in
the  direction  of  fewer  reversions  for  the  more  stringent  definitions  of
worsening/improvement.
  Table 3 shows the distribution by magnitude/confirmation of EDSS changes in SP and
RR subgroups. In SP, worsening >improvement but a substantial proportion of worsening
is offset by improvement events. However for RR, worsening was not significantly more
likely than improvement, even for 2 year definitions in subsets 1 and 3.Only for the 2-
year definition in subset 2 with incomplete 3-month data points was marginal significance
reached but not surviving correction for multiple comparisons p<0.07. The Wilcoxon was
not significant for this subgroup. The data for SP contrast with RR as there are many
more  individuals  who  have  worsened  for  all  degrees  of  change  and  the  number  of
improvements is proportionately less indicating the diminished measurement noise in SP.
Figs 1 and 2 near here
Survival  curves  for  SP  are  seen  in  Figs  1A-F  for  each  of  the  6  definitions  of
worsening/improvement listed in the Fig. legend, illustrating that sustained worsening is
more likely than similarly defined sustained improvement.  Table 4 shows that  for all
definitions of SP, worsening is significantly more likely than improvement using survival
analysis  (Kaplan-Meier).  Nevertheless,  difference  between  sustained  worsening  and
improvement rivals that between baseline and improvement.
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  The  RR  survival  curves  in  Figs  2  A-F  do  not  significantly  distinguish  between
worsening and improvement. The high frequency of “sustained improvement” in RRMS
is seen for all definitions. By 2 years, half of placebo arm patients would have a 0.5 pt.
decrease confirmed at 3 months, only slightly less often than for sustained progression.
Overall, the probabilities of 0.5 and 1.0 point changes at the 3-monthly intervals up to 2
years are remarkably similar in the K-M curves for sustained “improvement” vs sustained
worsening. For RR and SP patients, we truncated the data at 2 years to simulate a 2-year
trial, but no significant difference for RR is seen using all data points (Table 4). K-M
analysis  assumes  independence  of  the  curves,  which  is  not  strictly true,  and  we  are
comparing different events in the same patients, but potential overlap between patients
with worsening/improvement is limited by time constraints imposed by their definitions
and by trial durations.
  We asked if findings were an artefact of the EDSS levels reached. We hypothesised that
if  treatment failure definitions represented random noise/measurement error, we could
run the analysis in reverse, taking the last EDSS point as the first and the first as last. No
difference in the relative survival curves for improvement and worsening was found (not
shown). This further suggests that variation derived from rater and subject unrelated to
true disability level was measured.
Replication from the closed data set for the 1 point 6 month confirmed change in EDSS
in  subset  1  showed  again  no  significant  difference  between  sustained  worsening  vs
improvement (p=0.184).
Discussion
The problems of therapy evaluation in MS are mostly familiar. A chronic disease with
substantial  variation  in  short  and  long-term  outcome,  MS  has  proven  formidably
challenging. Recently, several therapies have been shown to favourably affect relapse-
related  clinical  and  MRI  outcomes7,12.  These  surrogates  for  unremitting  disability
accumulation, the primary medical and economic concern in MS, have heavily influenced
therapeutic  decisions,  making  validation  of  outcomes  used  in  trials  overdue.  An
independent data resource aimed at facilitating the discovery of effective treatments made
such validation analyses possible. The SLC database size facilitates generalizability of
findings, retesting of secondary hypotheses and replication.
  The disability scale (EDSS), ubiquitous in these trials, has clinical relevance at higher
levels  but  contains  weaknesses.  Some  variation  derives  from  inconsistent  subject
performance within the symptomatic spectrum of disease. Furthermore, progressive MS
cannot be confidently diagnosed in most patients until an EDSS of 4.0 on a 0-10 point
scale is reached. At this and higher levels, there is reasonably good agreement on scores
of ≥4. However for disability levels characterising trials claiming effectiveness in RRMS,
interrater variation is one point or greater 40% of the time8. Nevertheless, 0.5 or 1 point
changes7,13,14 have defined treatment failure for Kaplan-Meier curves in several pivotal
trials, conflicting with recommendations from the designer of the scale15 and with general
considerations about precision and accuracy. Measurements of changes smaller than the
variation intrinsic to the tool/object are considered inappropriate at best.
  Some patients  meeting criteria  for  treatment  failure in  these studies  must  do so by
random  variation/measurement  error.  For  quantification,  we  compared  worsening  to
improvement, each defined by magnitude and duration of +/- confirmed EDSS change in-
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trial.  These  results  support  EDSS-dependent  definitions  of  treatment  failure  used  in
progressive  MS trials,  but  the  degree of  variation  as  measured  by “improvement”  in
placebo-treated progressive cases was large. To the extent that sustained improvement is
a measure of noise or measurement error unrelated to unremitting progression, more than
half  of  treatment  failure  events  in  placebo-treated  progressive  cases  are  offset  by
“improvement”  events.  Accepting  random  variation/measurement  error  as  treatment
failure  surely  diminishes  power  of  studies  to  detect  effectiveness  and  increases
vulnerability of study conclusions to the influence of imperfect blinding16. Measurement
accuracy varies inversely with both variance and the square of bias.
  RRMS analyses contrast with the SP results.  Although greater change on the scale and
longer  confirmation  intervals  were  seen  to  increase  specificity  of  treatment  failure
definitions, no clinical measure of disability we evaluated can be supported as measuring
unremitting disability in RRMS. Changes of 0.5 points are unambiguously invalid, even
confirmed at 3 or 6 months. Similarly, 1 point changes were not significantly more likely
to occur for worsening than for improvement, although a trend appears in the expected
direction.  Survival  curves  were  almost  superimposable  for  all  definitions  and
worsening/improvement KM comparisons showed no statistical significance. The usual
course of RRMS is eventually manifested by sustained upward movement on the scale,
but 2 years in trial-eligible patients may be insufficient to show it. Selection for frequent
relapses  and  against  progressive  disease  may  well  bias  against  sustained  short-term
disability change.
  We considered that the findings reflected ascertainment idiosyncrasies of RR trials. In
these, pre-trial disease stability was usually required for 1-3 months, duration insufficient
to eliminate those who would improve spontaneously from recent relapse within the early
trial  period.  However,  after  excluding  the  first  data  point  and  effectively  extending
stability out to 4 - 6+ months for most cases, the relative survival curves for improvement
and worsening were essentially unaltered. Furthermore removal of values taken during
identified relapses had no impact on findings and conclusions (not shown).
  The pre-analysis division of the overall data set into two components (open/closed),
each separately and serially analysed, allowed for replication of results. Natural history
studies show that unremitting change requires an elapsed year for confirmation17  and in-
trial  times  less  than  this  have  been  associated  with  a  high  rate  of  spontaneous
reversion2,18,19. The findings do seem to mirror the degree of interrater variability8,20 and
have  major  implications  for  future  trial  design.  Our  own  recommendation  for
strengthening SP outcome criteria underestimated what is required21.
  If  “treatment  failure”  occurs  via  random  variation/measurement  error  or  remitting
relapses  but  is  misinterpreted or  misrepresented as  unremitting  disability,  progressive
erosion  of  study power  results.  Kaplan-Meier  analysis,  ubiquitous  in  MS  trials  and
appropriate  for  hard  endpoints,  is  unsuitable  for  trials  where  outcomes  are  highly
susceptible to random variation,  measurement error and relapses. Relapses are already
counted in  trials  as independent  outcomes.  It  will  require more careful  assessment  of
relapse  and  MRI  surrogates  to  put  clinical  outcomes  in  proper  context.  Meanwhile,
definitions  of  treatment  failure/unremitting  disability  change  require  reconsideration.
Clinical  decisions  in  RRMS  dependent  on  these  outcome measures  must  be  seen  as
outside an evidence base, notwithstanding the approval of the largest selling interferon by
the US FDA for the indication of preventing disability using measures evaluated here14.
Since worsening was no more frequent than improvement over 1-2 years in placebo arms
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of RRMS trials, debate regarding the propriety of placebo arms should not be concluded,
pending validation of relapse and MRI surrogates22. For the average MS patient having
0.5 attacks /year, 6 years of treatment equates to one attack prevented unless there is
concomitant reduction of disability. This has to be shown not assumed.
  The role of academic investigators and regulatory agencies in RRMS studies may also
warrant  review. Opponents  are reminded of the wide acceptance a decade ago of the
disability outcomes these studies could not validate23. Which disability outcomes should
be  relied  on  in  future  MS trials?  Increasing  the  degree  of  disability change and  the
duration of confirmation would increase power in SP studies and seems essential  for
meaningful disability results in RRMS. Despite oft-repeated claims that EDSS disability
measures  are  insensitive  to  change24,  reducing  measurement  error,  accounting  for
unblinding and extending the duration of trials may be more formidable obstacles to valid
conclusions.  However,  trial  sample  sizes  in  RRMS have  successively enlarged  while
duration has progressively shortened since the first pivotal interferon study12. A recent
FDA decision rested on surrogate markers and p-values in 12-month data25, the published
clinical results originally only 6 months. In contrast, we have had difficulty in this study
showing more worsening than improvement in two-year placebo data. 
  We have not had access to treatment  arm data  but  similar  limitations  for disability
outcomes  are  probable.  These  data  do  not  contradict  well-documented,  short-term
reductions of relapse rate and MRI T2 reported in RRMS trials21. Similar validation steps
for these surrogate measures are in process at the SLC.
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Table 1- Clinical characteristics of the study populations
Clinical
features
Data
features
Subset 1 Subset 2 Subset 3
MS type RR SP RR SP RR SP
N 254 171 262 254 216 237
gender male
female
male/N
70
184
0.28
72
99
0.42
64
198
0.24
111
143
0.44
54
162
0.25
106
131
0.45
Attacks
last  2
years
NA
median
range
mean
sd
27
3
0-8
3.0
1.37
2
1
0-8
1.3
1.49
52
3
0-8
3.0
1.30
6
1
0-8
1.2
1.43
49
3
0-8
3.1
1.34
6
1
0-8
1.2
1.44
Duration
in years
median
range
mean
sd
5.3
0.7-34.8
7.0
5.76
11.3
2.0-37.3
12.8
7.37
4.8
0.7-37.7
6.9
6.13
12.1
1.3-37.3
13.5
7.77
4.4
0.7-37.7
6.6
5.97
12.4
1.8-37.3
13.7
7.75
Age  at
onset
median
range
mean
sd
28
13-45
28.0
6.89
30
4-57
30.4
8.65
29
10-48
28.9
7.20
29
4-48
29.1
7.82
29.5
10-48
29.2
7.26
28.5
4-48
29.0
7.82
Age  at
study
entry
median
range
mean
sd
35
17-52
34.8
7.42
43
23-66
43.0
8.07
36
17-55
35.7
7.70
43
23-65
42.4
7.81
36
17-55
35.6
7.67
43
23-65
42.5
7.83
EDSS at
entry
median
range
mean
sd
2.5
0.0-5.5
2.6
1.20
4.0
1.5-5.5
4.4
0.79
2.5
0.0-6.5
2.7
1.34
5.5
3.0-6.5
5.3
1.06
2.5
0.0-6.5
2.6
1.28
5.5
3.0-6.5
5.3
1.05
Time  to
last obs.
in
months
median
range
mean
sd
24
15-51
23.8
6.64
33
15-39
28.7
8.69
10
Subset 1 -  at least 15 months every three months an observation and EDSS at baseline
<6.0
Subset 2 - at least one observation at two years  one month but no other restriction for
values after baseline, missing values allowed. 
Subset 3 - at least one observation at two years w/o potential relapses
obs. = observation and recording of EDSS score
Table 2: Worsening (progression or treatment failure-TF) and “improvement” (TI)
events and sustainability in RR and SP MS for definitions of disability treatment
failure  /improvement  used  in  MS.  Analyses  include  all  individuals  in  subset  1
without truncation
RRMS
Confim.
Period
EDSS
rise
progression
(TF)
improvement
(TI) TI events /TF+TI
No.
events
not
sust.*
No.
events
not
sust.*
None 0.5 178 119 160 120 0.473
None 1.0 124 67 100 62 0.446
3 months 0.5 113 46 122 73 0.519
3 months 1.0 68 16 60 25 0.469
6 months 0.5 84 23 86 40 0.506
6 months 1.0 46 6 45 12 0.495
SPMS
None 0.5 129 58 88 68 0.406
None 1.0 94 23 49 29 0.343
3 months 0.5 110 29 63 43 0.364
3 months 1.0 78 9 28 13 0.264
6 months 0.5 91 16 47 26 0.341
6 months 1.0 56 2 21 9 0.273
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*Sustained (sust.) - increase or decrease in score did not remit by the final evaluation
Table 3:  EDSS changes (N trial participants) for ½ point intervals from -2.5 - 5.0+
(in bold) over one/two years for subsets 1 and 3 in SP and RR trials*
subset N = -2.5 -2.
0
-1.
5
-1.0 -0.
5
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 p-value
A 254 1 4 13 32 44 81 39 19 10 6 3 1 0 1 0 0 0.793
B 161 0 6 9 15 30 39 24 18 8 3 4 3 0 1 1 0 0.187
C 216 4 9 13 17 34 52 33 18 13 6 8 1 0 4 3 1 0.082
D 171 1 1 7 14 24 47 32 26 7 6 3 2 1 0 0 0 0.002
E 112 0 0 1 9 10 20 26 19 13 5 5 3 0 1 0 0 <0.001
F 237 1 0 1 14 18 70 58 34 15 13 8 4 0 1 0 0 <0.001
p-values for one-sided Wilcoxon
A: 1 year RR subset 1 (median: 0.0, mean: -0.016)
B: 2 year RR subset 1 (median: 0.0, mean: 0.124)
C: 2 year RR subset 3 (median: 0.0, mean: 0.194)
D: 1 year SP subset 1 (median: 0.0, mean: 0.237)
E: 2 year SP subset 1(median: 0.5, mean: 0.638)
F: 2 year SP subset 3 (median: 0.5 mean: 0.508)
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Table 4: Statistical comparisons of survival curves for improvement vs. worsening
as defined by the use of confirmation and degree of EDSS change (columns I and II)
for the following patient groups: RR (all from subset 1), RR 2 years (data truncated
at 2 yrs) RR w/o 1st (first data point omitted) and for SP (all from subset 1)
Confirmation Rise RR  patients
Subset 1
RR truncated
at 2years
RR  w/o  1st
observation
SP  (all)
none 0.5 0.920 0.632 0.356 <0.001
none 1.0 0.107 0.082 0.225 <0.001
3 months 0.5 0.131 0.148 0.503 <0.001
3 months 1.0 0.860 0.913 0.417 <0.001
6 months 0.5 0.337 0.372 0.424 <0.001
6 months 1.0 0.788 0.812 0.893 <0.001
Log rank p-values for differences between survival plots.
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Figure 1: A-F Graphs for 171 subset 1 SP patients truncated after 2 years for the
following outcomes by EDSS change and presence/timing of confirmation. X- axis in
days, Y-axes - probability of not progressing/improving by same degree
A: no confirmation period, half point
B: 3 months confirmation period, half point
C: 6 months confirmation period, half point
D: no confirmation period, full point
E: 3 months confirmation period, full point
F: 6 months confirmation period, full point
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Figure 2: A-F Graphs for 254 RR patients subset 1; all observations were truncated
after 2 years. X-axes in days. Y-axes - probability of not progressing/improving by
same degree
A: no confirmation period, half point
B: 3 months confirmation period, half point
C: 6 months confirmation period, half point
D: no confirmation period, full point
E: 3 months confirmation period, full point
F: 6 months confirmation period, full point
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